Development Of A Modified Purification Process For A Monoclonal Antibody Therapeutic-Yield Improvement

A Mab product had been manufactured at the 2,000L scale and production at the 10,000L cGMP manufacturing scale was planned. Read how they improved yield of Mab product from bulk harvest by 1.8 fold by simplifying the downstream process in addition to eliminating the use of resins that were difficult to pack and resulted in declining yields with short life cycles.